CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of urothelial bladder carcinoma.
  
  LEARNING OBJECTIVES

  • Consider the recent FDA approval of pembrolizumab for high-risk non-muscle-invasive urothelial bladder cancer (UBC) that is unresponsive to BCG, and determine how this agent can be appropriately integrated into patient care.
  • Evaluate available data and ongoing studies investigating the use of anti-PD-1/PD-L1 antibodies as neoadjuvant therapy, and consider the current and potential role of this strategy.
  • Identify patients with previously untreated metastatic UBC (mUBC) appropriate for consideration of anti-PD-1/PD-L1 antibodies in combination with platinum-based chemotherapy.
  • Appreciate emerging data supporting the anti-PD-L1 antibody avelumab as maintenance therapy after response to first-line platinum-based chemotherapy for patients with mUBC, and incorporate this novel approach into management algorithms.
  • Recognize the FDA approval of erdafitinib for patients with advanced UBC with susceptible FGFR3 or FGFR2 genetic alterations whose disease has progressed during or after at least 1 line of platinum-containing chemotherapy, and determine how this agent may be appropriately integrated into clinical practice.
  • Recall pivotal clinical trial findings with enfortumab vedotin for previously treated locally advanced or metastatic UBC, and identify patients for whom treatment with this novel compound would be appropriate.
  • Consider how sacituzumab govitecan may be incorporated into the treatment algorithm on the basis of its recent FDA approval for patients with locally advanced or metastatic urothelial cancer who previously received a platinum-containing chemotherapy and an anti-PD-1/PD-L1 antibody.
  • Appraise available research data and ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies in combination with targeted agents or other immunotherapeutic strategies for mUBC, and counsel appropriately selected patients about participation in active research protocols.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Jonathan E Rosenberg, MD
  Chief, Genitourinary Medical Oncology Service
  Division of Solid Tumor Oncology
  Enno W Ercklentz Chair
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mirati Therapeutics, Pfizer Inc, QED Therapeutics, Seagen Inc, Tyra Biosciences; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, QED Therapeutics, Seagen Inc; Data and Safety Board: Almac Sciences; Honoraria: EMD Serono Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by an educational grant from Astellas and Seagen Inc.
  
  Release date: October 2021
  Expiration date: October 2022